Publications by authors named "Alexander D Douglas"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

4,110

Total Likes

373

Extended Reach

3,294,449

Social Features

282
R
Rabies glycoprotein engineering for improved stability and expression.
Solomon English, Sofiya Fedosyuk, Francisco Orliacq, Vincent Tem, William Taylor, Alexander D Douglas

Vaccine· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Routine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries.
Adam John Ritchie, Aronrag Meeyai, Caroline Trotter, Alexander D Douglas

Vaccine· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex.
Barnabas G Williams, Lloyd D W King, David Pulido, Doris Quinkert, Amelia M Lias, Alexander D Douglas

Nat Commun· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A screen for Plasmodium falciparum sporozoite surface protein binding to human hepatocyte surface receptors identifies novel host-pathogen interactions.
Rameswara R Segireddy, Hugo Belda, Annie S P Yang, Kirsten Dundas, Julia Knoeckel, Alexander D Douglas

Malar J· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerated and intensified manufacturing of an adenovirus-vectored vaccine to enable rapid outbreak response.
Carina C D Joe, Rameswara R Segireddy, Cathy Oliveira, Adam Berg, Yuanyuan Li, Alexander D Douglas

Biotechnol Bioeng· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration.
Cheng Zhang, Adam Berg, Carina C D Joe, Paul A Dalby, Alexander D Douglas

NPJ Vaccines· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid-response manufacturing of adenovirus-vectored vaccines.
Carina C D Joe, Nitin Chopra, Piergiuseppe Nestola, Julia Niemann, Alexander D Douglas

Nat Biotechnol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Meera Madhavan, Adam J Ritchie, Jeremy Aboagye, Daniel Jenkin, Samuel Provstgaad-Morys, Alexander D Douglas

EBioMedicine· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial.
Daniel Jenkin, Adam J Ritchie, Jeremy Aboagye, Sofiya Fedosyuk, Luke Thorley, Alexander D Douglas

Lancet Microbe· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies.
Weng M Ng, Sofiya Fedosyuk, Solomon English, Gilles Augusto, Adam Berg, Alexander D Douglas

Cell Host Microbe· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines.
Eriko Padron-Regalado, Marta Ulaszewska, Alexander D Douglas, Adrian V S Hill, Alexandra J Spencer

Sci Rep· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
Carina C D Joe, Jinlin Jiang, Thomas Linke, Yuanyuan Li, Sofiya Fedosyuk, Alexander D Douglas

Biotechnol Bioeng· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Maheshi N Ramasamy, Angela M Minassian, Katie J Ewer, Amy L Flaxman, Pedro M Folegatti, Alexander D Douglas

Lancet· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.
Pawan Dulal, Robabeh Gharaei, Adam Berg, Adam A Walters, Nicholas Hawkins, Alexander D Douglas

Sci Rep· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.
Pawan Dulal, Robabeh Gharaei, Adam Berg, Adam A Walters, Nicholas Hawkins, Alexander D Douglas

Sci Rep· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations.
Adam Berg, Daniel Wright, Pawan Dulal, Anna Stedman, Sofiya Fedosyuk, Alexander D Douglas

Vaccines (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Jordan R Barrett, Sandra Belij-Rammerstorfer, Christina Dold, Katie J Ewer, Pedro M Folegatti, Alexander D Douglas

Nat Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Katie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, Hannah Sharpe, Rebecca Makinson, Alexander D Douglas

Nat Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination.
Angela M Minassian, Sarah E Silk, Jordan R Barrett, Carolyn M Nielsen, Kazutoyo Miura, Alexander D Douglas

Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Katherine R W Emary, Tanya Golubchik, Parvinder K Aley, Cristina V Ariani, Brian Angus, Alexander D Douglas

Lancet· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Merryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, Lily Y Weckx, Pedro M Folegatti, Alexander D Douglas

Lancet· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Jordan R Barrett, Sandra Belij-Rammerstorfer, Christina Dold, Katie J Ewer, Pedro M Folegatti, Alexander D Douglas

Nat Med· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Katie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, Hannah Sharpe, Rebecca Makinson, Alexander D Douglas

Nat Med· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunological considerations for SARS-CoV-2 human challenge studies.
Alexander D Douglas, Adrian V S Hill

Nat Rev Immunol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis